CellaVision AB announces change in management team

CellaVision AB announces that CFO Magnus Blixt is leaving CellaVision AB to take on new challenges.

CellaVision's CFO Magnus Blixt announced today, May 14, 2025, that he will be stepping down from his role to take on new assignments and will leave the company on July 18, 2025.

"Magnus has made an invaluable contribution to CellaVision during his twelve years as CFO, with a broad responsibility for various administrative functions. His efforts have been crucial to our growth and success. We are grateful for his contributions and wish him all the best in his new assignments," says Simon Østergaard, CEO and President of CellaVision.

"My time at CellaVision has been a rewarding experience. It has been incredibly inspiring to witness the evolution of our technology, organization, and scalable business model that has delivered profitable growth over the years. With an expanded product portfolio and continued increased market presence, I look forward to following the company's ongoing journey," says Magnus Blixt.

The recruitment of a new CFO for CellaVision, and a potential interim solution, will start immediately.

Contact

Helena Raihle
Corporate Communications & Investor Relations
Tel: + 46 70 822 70 93
www.cellavision.com
helena.raihle@cellavision.com

About Us

CellaVision is a global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. These analyses play a vital role in swift and accurate disease diagnoses, particularly in cases of infections and serious cancer diseases. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company´s 12 local market support organizations covering more than 40 countries. In 2024, sales were SEK 723 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

This information is information that CellaVision is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-14 08:45 CEST.